Leukotriene receptor antagonists – risks and benefits for use in paediatric asthma

Bibliography

• CIBA GEIGY SYMPOSIUM: Terminology, definitions, and classifications of chronic pulmonary emphysema and related conditions. Thorax (1959) 14:286–299.
   Google Scholar
• UNGER L: The pathology of bronchial asthma. Arch. Intern. Med. (1922) 30:689–760.
   Google Scholar
• BURANAKUL B, WASHINGTON J, HILMAN B et al.: Causes of death during acute asthma in children. Am." Dis. Child. (1974) 128(3):343–350.
   Google Scholar
• BARNES PJ: Frontiers in medicine: new aspects of asthma. J. Intern. Med. (1992) 231:453–461.
   PubMed Web of Science ®Google Scholar
• MURPHY RC, HAMMARSTROM S, SAMUELSSON B: Leukotriene C, a slow reacting substance (SRS) from mouse mastocytoma cells. Proc. Natl. Acad Sri. USA (1979) 76:4275–4279.
   PubMed Web of Science ®Google Scholar
• DRAZEN JM, AUSTEN KF, LEWIS RA et al.: Comparative airway and vascular activities of leukotrienes C and D in vivo and in vitro. Proc. Natl. Acad. Sci. USA (1980) 77(7):4354–4358.
   PubMed Web of Science ®Google Scholar
• DAHLEN SE, HEDQVIST P, HAMMARSTROM S et al.: Leukotrienes are potent constrictors of human bronchi. Nature (1980) 288(5790):484–486.
   PubMed Web of Science ®Google Scholar
• GRIFFIN M, WEISS JW, LEITCH AG et al.: Effects of leukotriene D on the airways in asthma. N Eng] J. Med. (1983) 308(8):436–439.
   PubMed Web of Science ®Google Scholar
• SMITH LJ, GREENBERGER PA, PATTERSON R et al: The effect of inhaled leukotriene D4 in humans. Am. Rev Respir. Dis. (1985) 131(3):368–372.
   PubMed Web of Science ®Google Scholar
• WEISS JVV, DRAZEN JM, COLES N et al: Bronchoconstrictor effects of leukotriene C in humans. Science (1982) 216(4542):196–198.
   PubMed Web of Science ®Google Scholar
• SHIMIZU T, HIRANO H, MAJIMA Y et al.: A mechanism of antigen-induced mucus production in nasal epithelium of sensitized rats. A comparison with lipopolysaccharide-induced mucus production. Am. I Respir. Grit. Care Med. (2000) 161(5):1648–1654.
   PubMed Web of Science ®Google Scholar
• LAITINEN LA, LAITINEN A, HAAHTELA T et al.: Leukotriene E(4) and granulocytic infiltration into asthmatic airways. Lancet (1993) 341:989–990.
   PubMed Web of Science ®Google Scholar
• MUNOZ NM, LEFF AR: Blockade of eosinophil migration by 5-lipoxygenase and cyclooxygenase inhibition in explanted guinea pig trachealis. Am. J. Physic] (1995) 269:446–454.
   Google Scholar
• KELLAWAY CH, TRETHEWIE EW: Liberation of slow-reacting smooth muscle stimulating substance of anaphylaxis. J. Exp. Physic] (1940) 30:121–148.
   Google Scholar
• BROCKLEHURST WE: The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock. J. Physiol (1960) 151:416–435.
   PubMed Web of Science ®Google Scholar
• HOLGATE ST, BRADDING P, SAMPSON AP: Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. I Allergy Gin. Inonunol. (1996) 98:10–13.
   Google Scholar
• LYNCH KR, O'NEILL GP, LIU Q et al: Characterization of the human cysteinyl leukotriene cysLT1 receptor. Nature (1999) 399(6738):789–793.
   PubMed Web of Science ®Google Scholar
• HEISE CE, O'DOWD BE FIGUEROA DJ et al: Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem. (2000) 275(39):30531–30516.
   PubMed Web of Science ®Google Scholar
• ADELROTH E, MORRIS MM, HARGREAVE FE: Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. N Engl. J. Med. (1986) 315:480–484.
   PubMed Web of Science ®Google Scholar
• BARNES NC, PIPER PJ, COSTELLO JF: Comparative actions of inhaled leukotriene C4, leukotriene D4 and histamine in normal human subjects. Thorax (1984) 39:500–504.
   PubMed Web of Science ®Google Scholar
• PANETTIERI RA, TAN EM, CIOCCA V et al.: Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists. Am. I Respir Cell Mol Biol. (1998) 19(3):453–461.
   PubMed Web of Science ®Google Scholar
• LEWIS RA, AUSTEN KF, SOBERMAN RJ: Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N. Engl. J. Med. (1990) 323:645–655.
   Google Scholar
• CHUNG KF: Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Eur: Respir. J. (1995) 8:1203–1213.
   PubMed Web of Science ®Google Scholar
• MAROM Z, SHELHAMER JH, BACH MK et al.: Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am. Rev Respir. Dis. (1982) 126:449–451.
   PubMed Web of Science ®Google Scholar
• SHELHAMER JH, MAROM Z, SUN F et al.: The effects of arachinoids and leukotrienes on the release of mucus from human airways. Chest (1982) 81:36–37.
   PubMedGoogle Scholar
• MULDER A, GAUVREAU GM, WATSON RM et al.: Effect of inhaled leukotriene D4 on airway eosinophilia and airway hyperresponsiveness in asthmatic subjects. Am. I Respir. Crit. Care Med. (1999) 159:1562–1567.
   PubMed Web of Science ®Google Scholar
• DIAMANT Z, HILTERMANN JT, VAN RENSEN EL et al.: Cell differentials in induced sputum after inhaled leukotriene D4 in subjects with mild asthma. Am. J. Respir. Crit. Care Med. (1997) 155:1247–1253.
   Google Scholar
• SMITH LJ, GLASS M, MINKWITZ MC: Inhibition of leukotriene D4-induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219. Clin. Phapnacol. Ther. (1993) 54:430–436.
   PubMed Web of Science ®Google Scholar
• DE LEPELEIRE I, REISS TF, ROCHETTE F et al.: Montelukast causes prolonged, potent leukotriene D4 receptor antagonism in the airways of patients with asthma. Clin. Pharmaco] Ther. (1997) 61:83–92.
   PubMed Web of Science ®Google Scholar
• O'SHAUGHNESSY TC, GEORGIOU P,HOWLAND K et al.: Effect of pranlukast, an oral leukotriene receptor antagonist, on leukotriene D4 (LTD4) challenge in normal volunteers. Thorax (1997) 52:519–522.
   Google Scholar
• CALHOUN WJ, LAVINS BJ, MINKWITZ MC et al: Effect of zafirlukast (Accolate) on cellular mediators of inflammation. Bronchoalveolar lavage fluid findings after segmental antigen challenge. Am. J. Respic Grit. Care Med. (1998) 157:1381–1389.
   Google Scholar
• NAKAMURA Y, HOSHINO M, SIM JJ et al.: Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax (1998) 53:835–841.
   PubMed Web of Science ®Google Scholar
• KNORR B, MATZ J, BERNSTEIN JA et al.: Montelukast for chronic asthma in 6- to 14-year old children: a randomized, double-blind trial. JAMA (1998) 279:1181–1186.
   PubMed Web of Science ®Google Scholar
• ••One of few randomised, multi-centre trialsin children evaluating the effects of montelukast for mild, persistent asthma.
   Google Scholar
• REISS TF, CHERVINSKY P, DOCKHORN RJ et al: Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch. Intern. Med. (1998) 158:1213–1220.
   PubMed Web of Science ®Google Scholar
• O'BYRNE PM, DOLOVICH J, HARGREAVE FE: Late asthmatic responses. Am. Rev Respic Dir. (1987) 136:740–751.
   PubMed Web of Science ®Google Scholar
• DIAMANT Z, GROOTENDORST DC, VESELIC-CHARVAT M et al: The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin. Exp. Allergy (1999) 29(1):42–51.
   PubMed Web of Science ®Google Scholar
• MACFARLANE AJ, DWORSKI R, SHELLER JR et al.: Sputum cysteinyl leukotrienes increase 24 hours after allergen inhalation in atopic asthmatics. Am. J. Respic Grit. Care Med. (2000) 161(5):1553–1558.
   PubMed Web of Science ®Google Scholar
• O'SULLIVAN S, ROQUET A, DAHLEN B et al.: Urinary excretion of inflammatory mediators during allergen-induced early and late phase asthmatic reactions. Clin. Exp. Allergy (1998) 28:1332–1339.
   Google Scholar
• WENZEL SE, LARSEN GL, JOHNSTON K et al.: Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am. Rev Respir. Dis. (1990) 142:112–119.
   PubMed Web of Science ®Google Scholar
• MANNING PJ, ROKACH J, MALO JL et al.: Urinary leukotriene E4 levels during early and late asthmatic responses. I Allergy Clin. Immunol (1990) 86:211–220.
   PubMed Web of Science ®Google Scholar
• SMITH HR, LARSEN GL, CHERNIAK RM et al.: Inflammatory cells and eicosanoid mediators in subjects with late asthmatic responses and increases in airway responsiveness. Allergy Clin. Immunol (1992) 89:1076–1084.
   Google Scholar
• HAMILTON A, FAIFERMAN I, STOBER P et al: Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early and late phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. I Allergy Clin. Immunol (1998) 102:177–183.
   PubMed Web of Science ®Google Scholar
• RASMUSSEN JB, ERIKSSON LO, MARGOLSKEE DJ et al.: Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. I Allergy Clin. Immunol (1992) 90:193–201.
   PubMed Web of Science ®Google Scholar
• TAYLOR IK, O'SHAUGHNESSY KM, FULLER RW et al.: Effect of cysteinyl-leukotriene receptor antagonists ICI 204,219, on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet (1991) 337:690–694.
   Google Scholar
• FINDLAY SR, BARDEN JM, EASLEY CBet al.: Effect of the oral leukotriene antagonist, ICI 204,219 on antigen-induced bronchoconstriction in subjects with asthma. I Allergy Clin. Immunol (1992) 89:1040–1045.
   Google Scholar
• TANIGUCHI Y, TAMURA G, HONMA M et al.: The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. I Allergy Clin. Immunol (1993) 92:507–512.
   PubMed Web of Science ®Google Scholar
• LEIGH R, VETHANAYAGAM D, YOSHIDA M et al.: Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am. J. Respir. Grit. Care Med. (2002) 166(9):1212–1217.
   PubMed Web of Science ®Google Scholar
• SMITH CM, CHRISTIE PE, HAWKSWORTH RJ et al.: Urinary leukotriene E4 levels after allergen and exercise challenge in bronchial asthma. Am. Rev Respic Dis. (1991) 144:1411–1415.
   PubMed Web of Science ®Google Scholar
• MANNING PJ, WATSON RM, MARGOLSKEE DJ et al: Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl. J. Med. (1990) 323:1736–1739.
   PubMed Web of Science ®Google Scholar
• FINNERTY JP, WOOD-BAKER R, THOMSON H et al.: Role of leukotrienes in exercise-induced asthma: inhibitory effect of ICI 204,219, a potent leukotriene D4 receptor antagonist. Am. Rev Respic Dis. (1992) 145:746–749.
   PubMed Web of Science ®Google Scholar
• PEARLMAN DS, OSTROM NK, BRONSKY EA et al.: The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children. I Pediam. (1999) 134:273–279.
   Web of Science ®Google Scholar
• ••Important study that looked at children aged6–14 years with EIB. Evaluated the efficacy and safety of zafirlukast for inhibiting EIB.
   Google Scholar
• KEMP JP, DOCKHORN RJ, SHAPIRO GG et al.: Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. Pediatr. (1998) 133(3):424–428.
   Web of Science ®Google Scholar
• ••Studied the effects of montelukast inpreventing EIB in children.
   Google Scholar
• LEFF JA, BUSSE WW, PEARLMAN D et al: Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N. Engl. J. Med. (1998) 339:147–152.
   PubMed Web of Science ®Google Scholar
• •Adult trial that studied the effects of montelukast in controlling mild asthma and EIB.
   Google Scholar
• HOFSTRA WB, STERK PJ, NEIJENS HJ et al: Short-term treatment with zafirlukast, sodium cromoglycate or placebo in reducing exercise induced bronchoconstriciton in adolescent asthmatics. Eur: Respic J. (1997) 10(Suppl.):220. Abstract.
   Google Scholar
• EDELMAN JM, TURPIN JA, BRONSKY EA et al.: Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Ann. Intern. Med. (2000) 132(2):97–104.
   PubMed Web of Science ®Google Scholar
• MCFADDEN ER, GILBERT IA: Exercise-induced asthma. N Engl. I Med. (1994) 330:1362–1367.
   PubMed Web of Science ®Google Scholar
• SIMONS FE, GERSTNER TV, CHEANG MS: Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics (1997) 99(5):655–659.
   PubMed Web of Science ®Google Scholar
• RAMAGE L, LIPWORTH BJ, INGRAM CG et al.: Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir. Med. (1994) 88:363–368.
   PubMed Web of Science ®Google Scholar
• BOULET LP, BECKER A, BERUBE D et al.: Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group. Can. Med. Assoc. .1. (1999) 161(11Suppl.):S1–S61.
   Google Scholar
• ••Important consensus statement regardingthe diagnosis and treatment of asthma with recommendations for childhood asthma.
   Google Scholar
• NIH/NHLBI: Guidelines for the diagnosis and management of asthma. US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute. Bethesda, MD, USA (2002).
   Google Scholar
• ••Important consensus statement regardingthe diagnosis and treatment of asthma with recommendations for childhood asthma.
   Google Scholar
• GINA: Global Strategy for Asthma Management it Prevention Workshop Report, National Institutes of Health.
   Google Scholar
• ••Important consensus statement regardingthe diagnosis and treatment of asthma with recommendations for childhood asthma.
   Google Scholar
• SPECTOR SL, SMITH LJ, GLASS M: Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am. J. Respir. Crit. Care Med. (1994) 150(3):618–623.
   PubMed Web of Science ®Google Scholar
• SUISSA S, DENNIS R, GREENBERGER PA et al.: Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: a randomized double-blind, placebo-controlled trial. Am. J. Respir. Crit. Care Med. (1997) 126:177–183.
   Google Scholar
• KNORR B, FRANCHI LM, BISGAARD H et al.: Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics (2001) 108(3):E48.
   PubMed Web of Science ®Google Scholar
• •Studied the safety and efficacy of montelukast for children aged 2–5 years with persistent asthma.
   Google Scholar
• PEARLMAN DS, LAMPL KL, DOWLING PJ, MILLER CJ, BONUCCELLI CM: Effectiveness and tolerability of zafirlukast for the treatment of asthma in children. Clin. The]: (2000) 22:732–747.
   PubMed Web of Science ®Google Scholar
• ••Large, multi-centre trial evlauating the efficacy and safety of zafirlukast in children with mild persistent asthma.
   Google Scholar
• MALMSTROM K, ROD RIGUEZ-GOMEZG, GUERRA J et al.: Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/beclomethasone study group. Ann. Intern. Med. (1999) 130(6):487–495.
   PubMed Web of Science ®Google Scholar
• ••Large, multi-centre trial comparing ICSto LTRA in patients with moderate, persistent asthma.
   Google Scholar
• DRAZEN JM, YANDAVA CN, DUBE L et al: Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat. Genet. (1999) 22:168.
   PubMed Web of Science ®Google Scholar
• WECHSLER ME, ISRAEL E: Pharmacogenetics of treatment with leukotriene modifiers. Carr: Opin. Allergy Clin. Immunol (2002) 2:395–401.
   PubMedGoogle Scholar
• CYLLY A, KARA A, OZDEMIR T et al: Effects of oral montelukast on airway function in acute asthma. Respir. Med. (2003) 97:533–536.
   PubMed Web of Science ®Google Scholar
• CAMARGO CA, SMITHLINE HA, MALICE MP et al.: A randomized, controlled trial of intravenous montelukast in acute asthma. Am. J. Respir. Crit. Care Med. (2003) 167:528–533.
   PubMed Web of Science ®Google Scholar
• DICPINIGAITIS PV, DOBKIN JB, REICHEL J: Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma. J. Asthma (2002) 39:291–297.
   PubMed Web of Science ®Google Scholar
• KRAWIEC ME, WESTC OTT JY, CHU HW et al.: Persistent wheezing in very young children is associated with lower respiratory inflammation. Am. .1. Respir. Crit. Care Med. (2001) 163:1338–1343.
   Google Scholar
• ••One of few studies to evaluate theinflammatory process that occurs in children with wheezing.
   Google Scholar
• CROCKER IC, ZHOU CY, BEWTRA AK et al.: Glucocorticosteroids inhibit leukotriene production. Ann. Allergy Asthma Immunol (1997) 78:497–505.
   PubMed Web of Science ®Google Scholar
• VAN SCHAIK SM, TRISTAM DA, NAGPAL IS et al.: Increased production of IFN-y and cysteinyl leukotrienes in virus-induced wheezing. I Allergy Gin. Immunol (1999) 103(4):630–636.
   PubMed Web of Science ®Google Scholar
• VOLOVITZ B, WELLIVER RC, DE CASTRO G et al: The release of leukotrienes in the respiratory tract during infection with respiratory syncytial virus: role in obstructive airway disease. Pediam. Res. (1988) 24:504–507.
   PubMed Web of Science ®Google Scholar
• VOLOVITZ B, FADEN H, OGRA PL: Release of leukotriene C4 in respiratory tract during acute viral infection. Pediam. (1988) 112:218–222.
   Google Scholar
• BISGAARD H: A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am. .1. Respir. Crit. Care Med. (2003) 167:379–383.
   Google Scholar
• •Small trial that evaluated the effect of montelukast on post-viral wheeze.
   Google Scholar
• LOFDAHL CG, REISS TF, LEFF JA et al.: Randomized, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. Br. Med. J. (1999) 319:87–90.
   PubMed Web of Science ®Google Scholar
• •Important trial looking at whether montelukast could benefit patients by allowing ICS doses to be tapered.
   Google Scholar
• TAMAOKI J, KONDO M, SAKAI N et al: Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am. J. Respir. Crit. Care Med. (1997) 155:1235-1240. ao. TOHDA Y, FUJIMURA M, TANIGUCHI H et al: Leukotriene receptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthmatic patients. Clin. Exp. Allergy (2002) 32:1180–1186.
   Google Scholar
• LAVIOLETTE M, MALMSTROM K, LU S et al.: Montelukast added to inhaled beclomethasone in treatment of asthma. Am. J. Respir. Crit. Care Med. (1999) 160(6):1862–1868.
   PubMed Web of Science ®Google Scholar
• •Evaluated the benefits of adding montelukast to ICS for control of moderate, persistent asthma.
   Google Scholar
• VIRCHOW JC, PRASSE A, NAYA I et al.: Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am. Respir. Crit. Care Med (2000) 162(2):578–585.
   PubMed Web of Science ®Google Scholar
• •Evaluated the benefits of adding zafilukast to ICS for moderate-to-severe, persistent asthma.
   Google Scholar
• BUSSE WW, NELSON H, WOLFE J et al: Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. Allergy Clin. Immunol (1999) 103:1075–1080.
   Google Scholar
• NELSON HS, BUSSE WW, KERWIN E et al.: Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. I Allergy Clin. bronunol (2000) 106(6):1088–1095.
   PubMed Web of Science ®Google Scholar
• SIMONS FE, VILLA JR, LEE BW et al:Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. Pediatr. (2001) 138(5):694–698.
   Web of Science ®Google Scholar
• PHIPATANAKUL W, GREENE C, DOWNES SJ et al.: Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids. Ann. Allergy Asthma Innnunol (2003) 91(1):49–54.
   PubMed Web of Science ®Google Scholar
• VOLOVITZ B, TABACHNIK E, NUSSINOVITCZ M et al.: Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in respiratory tract of children with persistent asthma. I Allergy Olin. Inonunol. (1999) 104:1162–1167.
   PubMed Web of Science ®Google Scholar
• •Important study in children that demonstrated a decrease in inflammation in the respiratory tract after treatment with montelukast.
   Google Scholar
• MASPERO JF, DUENAS-MEZA E, VOLOVITZ B et al.: Oral montelukast versus beclomethasone in 6–11 year old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction and adherence with therapy. Carr: Med. Res. Opin. (2001) 17:96–104.
   Google Scholar
• NATHAN RA, MINKWITZ MC, BONUCCELLI CM: Two first-line therapies in the treatment of mild asthma: use of peak flow variability as a predictor of effectiveness. Ann. Allergy Asthma Inonunol. (1999) 82:497–503.
   PubMed Web of Science ®Google Scholar
• DUCHARME FM: Inhaled glucocorticoidsversus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. Br. Med. (2003) 326:621.
   PubMed Web of Science ®Google Scholar
• •Review of current literature citing 1 paediatric and 12 adult trials that have looked at ICS versus LTRAs for control of asthma.
   Google Scholar
• BUKSTEIN DA, LUSKIN AT, BERNSTEIN A: 'Real-world' effectiveness of daily controller medicine in children with mild persistent asthma. Ann. Allergy Asthma Innnunol. (2003) 90(5):543–549.
   PubMed Web of Science ®Google Scholar
• ARMSTRONG EP, MALONE DC: Fluticasone is associated with lower asthma-related costs than leukotriene modifiers in a real world analysis. Phapnacotherapy (2002) 22:1117–1123.
   PubMed Web of Science ®Google Scholar
• KATIAL RK, STELZLE RC, BONNER MW, MARINO M, CANTILENA LR, SMITH LJ: A drug-interaction between zafirlukast and theophylline. Arch. Intern. Med. (1998) 158:1713–1715.
   PubMed Web of Science ®Google Scholar
• GREEN RL, VAYONIS AG: Churg-Strauss syndrome after zafirlukast in two patients not receiving steroid treatment. Lancet (1999) 353:725–726.
   PubMed Web of Science ®Google Scholar
• KINOSHITA M, SHIRAISHI T, KOGA Tet al.: Churg-Strauss syndrome after corticosteroid withdrawal in an asthmatic patient treated with pranlukast. Allergy Olin. bronunol (1999) 103(3 Pt 1):534–535.
   Google Scholar
• WECHSLER ME, GARPESTAD E, FLIER SR et al: Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA (1998) 279(6):455–457.
   PubMed Web of Science ®Google Scholar
• WECHSLER ME, FINN D, GUNAWARDENA D et al: Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest (2000) 117:708–713.
   PubMed Web of Science ®Google Scholar
• MARTIN RM, WILTON LV, MANN RD: Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated condition: retrospective analysis of 58 prescription-event monitoring cohort studies. Phannacoepidennol Drug Sal: (1999) 8:179.
   PubMed Web of Science ®Google Scholar
• TUGGEY JM, HOSKER HS: Churg-Strauss syndrome associated with montelukast therapy. Thorax (2000) 55:805–806.
   PubMed Web of Science ®Google Scholar
• JAMALEDDINE G, DIAB K, TABBARAH Z et al.: Leukotriene antagonists and the Churg-Strauss syndrome. &min. Arthritic Rheum. (2002) 31:218–227.
   PubMed Web of Science ®Google Scholar
• SCHURMAN SJ, ALDERMAN JM, MASSANARI M et al.: Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast. Chest (1998) 114:1220–1223.
   PubMed Web of Science ®Google Scholar